Rifaximin Improves Gut Dysbiosis in Insulin Resistance and Type 2 Diabetes

Zagazig University

Status: Unknown

Conditions: Type2 Diabetes

Treatments: Drug: Rifaximin 200 MG

Study type: Interventional

Funder types: Other

Identifiers

NCT03758144

4493

Details and patient eligibility

About

Gut Dysbiosis had been involved in some way in the pathogenesis of some extra-intestinal disorders including metabolic syndrome, cardiovascular disease, and obesity.

Full description

Accumulating evidence had linked metabolic syndrome and diabetes to dysequilibrium in gut microbiota, which are a critical regulator of host metabolism and immune responses. gut microbiota interacts with host signaling pathways, leading to modulation of the endocrine system, immune responses. gut microbial metabolites, in particular, short-chain fatty acids, have been significantly associated with liability to diabetes. patients with positive fecal short-chain fatty acids will be given rifaximin

Enrollment: 80 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diabetes with gut dysbiosis

Exclusion criteria

• recent antibiotic use
• pregnancy
• diabetogenic drugs

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

80 participants in 2 patient groups

study

Active Comparator group

Treatment:

Drug: Rifaximin 200 MG

CONTROL GROUP

No Intervention group